The project aims to improve cochlear implant performance via integrated gene therapy. A neurotrophin gene cassette will be delivered to cells adjacent to the electrode array using electrical pulses. This drives regeneration of the auditory nerve fibres and considerably improves cochlear implant performance. This study will optimize the therapeutic gene construct and cochlear implant –based gene delivery controller, and undertake an initial clinical trial to evaluate safety and efficacy.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.